BIOMAT Database Logo BIOMAT Database Logo

Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation--preliminary results. 1999

R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Transplantation Institute, The Medical University of Warsaw, Poland.

Monoclonal and polyclonal antilymphocyte antibodies have been used successfully in organ transplantation as induction therapy and in the treatment of acute graft rejection. Used for induction the medication is generally given for the first 7-10 days. The aim of this study was to assess the safety and efficacy of single high dose (9 mg/kg) ATG Fresenius S given perioperatively, before revascularization, to kidney allograft recipients. During last twelve months seventy six, first cadaveric kidney adult recipients were included into the study in two centers (center A-64, center B-12). All patients received triple drug immunosuppression (Neoral, steroids and Cellcept which was replaced by azathioprine after 4 months), and were randomized to receive ATG or not. The follow-up period ranged from 1 month up to 1 year. The preliminary results are very promising, the rejection rate in bolus group was significantly lower than in control. No significant side effects or serious adverse events in both groups were observed.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002102 Cadaver A dead body, usually a human body. Corpse,Cadavers,Corpses
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation.
July 2003, Molecular immunology,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
December 1998, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience.
January 2009, Annals of transplantation,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
January 2007, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation.
November 1997, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
March 2005, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Use of ATG-Fresenius as an Induction Agent in Deceased-Donor Kidney Transplantation.
April 2017, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
ATG-Fresenius S combined with cyclosporine a: an effective immunosuppressive therapy for children with aplastic anemia.
July 2014, Journal of pediatric hematology/oncology,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Efficacy and Safety of ATG-Fresenius as an Induction Agent in Living-Donor Kidney Transplantation.
April 2017, Transplantation proceedings,
R Samsel, and A Chmura, and Z Włodarczyk, and J Wyzgał, and T Cieciura, and B Lagiewska, and J Pliszczyński, and G Korczak, and T Lazowski, and L Paczek, and J Wałaszewski, and M Lao, and W Rowiński
Single-dose rituximab as induction in renal transplantation.
May 2010, Transplantation,
Copied contents to your clipboard!